PPARγ activation has been shown to reduce WBC‐mediated inflammation in metabolic disease and certain cancers, raising the question of whether targeted PPARγ agonism could improve outcomes by restoring adipose function and mitigating paracrine tumor support. This evidence concerns the gene PPARG and neoplasm.